Nicotinamide Riboside Supplementation In Progressive Multiple Sclerosis (Norseman)

Nicotinamide Riboside Supplementation In Progressive Multiple Sclerosis (Norseman)

ClinicalTrials.gov ID: NCT05740722
Sponsor: Haukeland University Hospital
Information provided by: Haukeland University Hospital (Responsible Party)
Last Update Posted: 2024-01-11

Brief Summary:
The purpose of this study is to assess the safety and efficacy of Nicotinamide riboside (NR) for treatment of patients with progressive multiple sclerosis.

The main question it aims to answer is:
- Does NR delay disability progression in progressive multiple sclerosis?

Participants will be treated with NR or placebo for 30 months,

Detailed Description:
After being informed about the study and risks, all patients giving written informed consent will undergo a screening period to determine eligibility for study entry.

At baseline patients who meet the eligibility requirements will be randomised in a double- blinded manner (patient and investigator) in a 1:1 ratio to nicotinamide riboside (1000 mg daily) or placebo (once a day)

OFFICIAL TITLE
Nicotinamide Riboside Supplementation In Progressive Multiple Sclerosis: A Randomised Controlled Trial: The NORSEMAN Study

INTERVENTION / TREATMENT
Dietary Supplement: Nicotinamid riboside
Dietary Supplement: Placebo